GKB Ophthalmics Ltd has submitted a regulatory disclosure to BSE Limited confirming that its promoters and promoter group have not encumbered any shares during the financial year ended March 31, 2026. The disclosure was filed on April 02, 2026, in compliance with SEBI Takeover Regulations.

Regulatory Compliance Details

The disclosure was made under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011. This regulation requires promoters to confirm the status of share encumbrances at the end of each financial year.

Promoter Declaration

Krishna Gopal Gupta, acting on behalf of the promoter group, confirmed that no encumbrance of shares was made directly or indirectly during the specified financial year. The declaration covers all promoters, promoter group members, and persons acting in concert with GKB Ophthalmics Limited.

Corporate Information

GKB Ophthalmics Limited is headquartered at 16-A, Tivim Industrial Estate, Mapusa, Goa 403526. The company secretary Pooja Bicholkar facilitated the regulatory filing process. The disclosure was also copied to the company's Audit Committee as part of internal governance procedures.

Significance of Disclosure

This regulatory filing ensures transparency in promoter shareholding and compliance with SEBI's takeover regulations. The confirmation of no share encumbrances provides clarity to investors and stakeholders regarding the promoter group's shareholding status during FY26.

GKB Ophthalmics Ltd. conducted its annual independent directors meeting on March 18, 2026, fulfilling regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies Act, 2013. The meeting represents a key governance milestone for the pharmaceutical company for the year 2025-26.

Meeting Attendance and Composition

The independent directors meeting saw full attendance from all three independent board members:

Key Agenda Items and Assessments

The independent directors conducted comprehensive evaluations across multiple governance areas during their session. The meeting agenda focused on three primary assessment areas as mandated by regulatory frameworks.

The directors reviewed the performance of non-independent directors and evaluated the board's overall effectiveness. Additionally, they assessed the performance of the company's chairperson, incorporating feedback from both executive and non-executive directors to ensure a balanced evaluation process.

Information Flow Assessment

A critical component of the meeting involved evaluating the quality, quantity, and timeliness of information flow between GKB Ophthalmics' management and the board. This assessment ensures that directors receive adequate and timely information necessary for effective decision-making and oversight responsibilities.

Meeting Duration and Compliance

The meeting was formally communicated to BSE Limited through the company secretary, Pooja Bicholkar, ensuring transparency and compliance with listing obligations. This independent directors meeting forms part of GKB Ophthalmics' ongoing commitment to maintaining robust corporate governance standards in the pharmaceutical sector.